Transplant Genomics has announced a collaboration with the Mayo Clinic to develop, validate, and commercialize diagnostic tests enabling personalized immunosuppression for solid organ transplant recipients. As part of the multiyear collaboration, Mayo Clinic will make an investment in Transplant Genomics for an undisclosed amount.
Additionally, both companies with work together on co-development of new tests and technologies for additional targets, including exploratory studies in heart and liver transplantation.
Physicians and researchers are participating at Mayo Clinic campuses in Arizona, Florida and Rochester, Minnesota. Principal investigators include: Mark Stegall, M.D., Raymond Heilman, M.D., and Martin Mai, M.D., Mayo Clinic Transplant Center. Continue reading
from Donate Life Organ and Tissue Donation Blog℠ http://ift.tt/29aLnbq
0 comments:
Post a Comment
Click to see the code!
To insert emoticon you must added at least one space before the code.